BR112023001734A2 - Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação - Google Patents
Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulaçãoInfo
- Publication number
- BR112023001734A2 BR112023001734A2 BR112023001734A BR112023001734A BR112023001734A2 BR 112023001734 A2 BR112023001734 A2 BR 112023001734A2 BR 112023001734 A BR112023001734 A BR 112023001734A BR 112023001734 A BR112023001734 A BR 112023001734A BR 112023001734 A2 BR112023001734 A2 BR 112023001734A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulations
- articles
- manufacture
- methods
- autoinjectors
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 238000009472 formulation Methods 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063059427P | 2020-07-31 | 2020-07-31 | |
| PCT/US2021/043690 WO2022026699A1 (en) | 2020-07-31 | 2021-07-29 | Anti-integrin beta7 antibody formulations and devices |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001734A2 true BR112023001734A2 (pt) | 2023-02-28 |
Family
ID=77693570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001734A BR112023001734A2 (pt) | 2020-07-31 | 2021-07-29 | Formulações, artigos de fabricação, autoinjetores e métodos para tratar um distúrbio inflamatório gastrointestinal em um indivíduo e para administrar por via subcutânea uma formulação |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4188958A1 (he) |
| JP (1) | JP2023536158A (he) |
| KR (1) | KR20230041071A (he) |
| AR (1) | AR123085A1 (he) |
| AU (1) | AU2021316017A1 (he) |
| BR (1) | BR112023001734A2 (he) |
| CA (1) | CA3190109A1 (he) |
| IL (1) | IL300133A (he) |
| MX (1) | MX2023001157A (he) |
| TW (1) | TW202222832A (he) |
| WO (1) | WO2022026699A1 (he) |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| EP0546073B1 (en) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production and use of transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク． | 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| EP1222292B1 (en) | 1999-10-04 | 2005-08-31 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP2116265B1 (en) | 2000-10-12 | 2020-12-23 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| HUE058817T2 (hu) | 2004-09-03 | 2022-09-28 | Genentech Inc | Humanizált anti-béta7 antagonisták és alkalmazásaik |
| KR101361905B1 (ko) | 2008-05-16 | 2014-02-21 | 제넨테크, 인크. | 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도 |
| TW201039854A (en) | 2009-03-06 | 2010-11-16 | Genentech Inc | Antibody formulation |
| LT2704742T (lt) * | 2011-05-02 | 2017-10-25 | Millennium Pharmaceuticals, Inc. | Anti-alfa4beta7 antikūno kompozicija |
| USRE49197E1 (en) | 2011-06-17 | 2022-09-06 | Shl Medical Ag | Injection device |
| AU2012269770B2 (en) | 2011-06-17 | 2015-04-16 | Shl Medical Ag | Injection device |
| WO2014160753A1 (en) | 2013-03-27 | 2014-10-02 | Genentech, Inc. | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
| CA2939246A1 (en) | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| WO2016138207A1 (en) * | 2015-02-26 | 2016-09-01 | Genentech, Inc. | Integrin beta7 antagonists and methods of treating crohn's disease |
| WO2019246455A1 (en) * | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
-
2021
- 2021-07-29 AU AU2021316017A patent/AU2021316017A1/en active Pending
- 2021-07-29 BR BR112023001734A patent/BR112023001734A2/pt not_active Application Discontinuation
- 2021-07-29 CA CA3190109A patent/CA3190109A1/en active Pending
- 2021-07-29 AR ARP210102115A patent/AR123085A1/es unknown
- 2021-07-29 JP JP2023506189A patent/JP2023536158A/ja active Pending
- 2021-07-29 WO PCT/US2021/043690 patent/WO2022026699A1/en active Application Filing
- 2021-07-29 KR KR1020237006223A patent/KR20230041071A/ko unknown
- 2021-07-29 MX MX2023001157A patent/MX2023001157A/es unknown
- 2021-07-29 EP EP21766732.8A patent/EP4188958A1/en not_active Withdrawn
- 2021-07-29 TW TW110127937A patent/TW202222832A/zh unknown
- 2021-07-29 IL IL300133A patent/IL300133A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021316017A1 (en) | 2023-02-16 |
| CA3190109A1 (en) | 2022-02-03 |
| JP2023536158A (ja) | 2023-08-23 |
| TW202222832A (zh) | 2022-06-16 |
| IL300133A (he) | 2023-03-01 |
| WO2022026699A1 (en) | 2022-02-03 |
| KR20230041071A (ko) | 2023-03-23 |
| EP4188958A1 (en) | 2023-06-07 |
| MX2023001157A (es) | 2023-02-22 |
| AR123085A1 (es) | 2022-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123586T1 (el) | Υποδορια σκευασματα αντισωματος her2 | |
| Rios-Doria et al. | Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models | |
| BR112019022972A2 (pt) | Fomulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e métodos de uso das mesmas | |
| CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| BR112018008326A2 (pt) | composições e métodos para o tratamento de câncer | |
| BR112017019978A2 (pt) | anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo | |
| BR112014021102A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo | |
| CL2018000705A1 (es) | Método de cristalización y biodisponibilidad | |
| BR112014021101A2 (pt) | Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo | |
| BR112014016672A2 (pt) | compostos de carbamato e sua preparação e uso | |
| BR112016026811A2 (pt) | formulação de anticorpo | |
| MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| BR112016022318A2 (pt) | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo | |
| BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| MX2022001896A (es) | Formulaciones anti-c5 de alta concentracion. | |
| BR112022012514A2 (pt) | Formas de dosagem sólidas que contêm bactérias e vesículas extracelulares microbianas | |
| EP3541943A4 (en) | MICRO-ORGANISM FOR ADMINISTERING A MEDICINAL PRODUCT FOR THE TREATMENT OF A GASTROINTESTINAL DISEASE, WHICH EXPRESSES AND SECRETS P8 PROTEIN, AND PHARMACEUTICAL COMPOSITION CONSISTING OF THIS MICRO-ORGANISM FOR THE PREVENTION OR TREATMENT OF A GASTROINTESTINAL DISEASE | |
| BR112021014854A2 (pt) | Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis | |
| MX2023015070A (es) | Anticuerpo anti-cd40, fragmento de union a antigeno y uso medico del mismo. | |
| MX2023009971A (es) | Composicion farmaceutica que contiene anticuerpo anti-tslp. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |